Is Sppi a good stock?
Is Sppi a good stock?
Spectrum Pharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Why is SPPI stock dropping?
The big decline came after the company announced that the U.S. Food and Drug Administration turned down approval of Rolontis in treating neutropenia in patients receiving cancer drugs that decrease bone marrow activity.
Does SPPI stock pay dividends?
SPPI does not currently pay a dividend.
Will Sppi go up?
The 5 analysts offering 12-month price forecasts for Spectrum Pharmaceuticals Inc have a median target of 4.00, with a high estimate of 10.00 and a low estimate of 3.00. The median estimate represents a +466.65% increase from the last price of 0.71.
Will Sppi go back up?
On average, analysts forecast that SPPI’s EPS will be -$0.55 for 2022, with the lowest EPS forecast at -$0.71, and the highest EPS forecast at -$0.37. On average, analysts forecast that SPPI’s EPS will be -$0.10 for 2023, with the lowest EPS forecast at -$0.28, and the highest EPS forecast at $0.06.
Will Sppi get FDA approval?
–(BUSINESS WIRE)– Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today that the U.S. Food and Drug Administration (FDA) has granted Accelerated Approval of Beleodaq™ for the …
Will Rolontis get approved?
Rolontis obtained the Ministry of Food and Drug Safety’s approval in March, becoming Hanmi’s first biologic drug and the nation’s 33rd novel drug.
Did Rolontis get approved?
Who owns SPPI stock?
Top 10 Owners of Spectrum Pharmaceuticals Inc
| Stockholder | Stake | Shares owned |
|---|---|---|
| Armistice Capital LLC | 9.65% | 17,100,000 |
| BlackRock Fund Advisors | 7.24% | 12,817,131 |
| D. E. Shaw & Co. LP | 4.43% | 7,845,726 |
| The Vanguard Group, Inc. | 4.32% | 7,646,403 |
Is Rolontis approved?
The FDA had previously issued a CRL due to manufacturing issues for the therapy, which is seeking an indication for preventing infections after chemotherapy for breast cancer. The agency has set a new PDUFA date of September 9, 2022.
Did Sppi get FDA approval?
What is Rolontis for?
About ROLONTIS ROLONTIS is a novel, long-acting granulocyte colony-stimulating factor (G-CSF) seeking an indication for the treatment of neutropenia in patients receiving myelosuppressive anti-cancer drugs.
Is Poziotinib FDA approved?
FDA Accepts New Drug Application for Poziotinib in HER2 Exon 20+ NSCLC. A new drug application has been accepted by the FDA for poziotinib in patients with advanced or metastatic non–small cell lung cancer with HER2 exon 20 insertion mutations.
What is Rolontis?
ROLONTIS is a novel, long-acting granulocyte colony-stimulating factor (G-CSF) seeking an indication for the treatment of neutropenia in patients receiving myelosuppressive anti-cancer drugs.
Is Adagrasib FDA approved?
The FDA has accepted a new drug application (NDA) for adagrasib (MRTX 849) as treatment for patients with previously treated KRAS G12C–positive non–small cell lung cancer (NSCLC), according to a press release from drug developer Mirati Therapeutics.
Will Rolontis be approved?
What is Repotrectinib?
Repotrectinib (repotrectinib, TPX-0005) is an orally-available multi-kinase inhibitor designed to overcome resistance due to solvent-front substitutions involving TRKA, TRKB, and TRKC proteins as well as those involving ROS1, and ALK [1, 2].
What is breakthrough therapy status?
A breakthrough therapy designation is for a drug that treats a serious or life-threatening condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint(s) over available therapies.
Is Repotrectinib FDA approved?
The FDA has granted breakthrough therapy designation (BTD) to repotrectinib (TPX-0005) for treatment use in patients with ROS1-positive metastatic non-small cell lung cancer (NSCLC) who have previously been treated with a ROS1 tyrosine kinase inhibitor and who have not received prior platinum-based chemotherapy.
